Olig2 (211F1.1) Mouse Monoclonal Antibody
SIGMA/387M-1
Product Type: Chemical
Immunohistochemistry Olig2 (211F11) on oligodendroglioma
| antibody form | culture supernatant |
| antibody product type | primary antibodies |
| biological source | mouse |
| clone | 211F1.1, monoclonal |
| conjugate | unconjugated |
| control | astrocytoma |
| description | For In Vitro Diagnostic Use in Select Regions (See Chart) |
| form | buffered aqueous solution |
| isotype | IgG2aκ |
| manufacturer/tradename | Cell Marque™ |
| packaging | bottle of 1.0 mL predilute (387M-17) |
| bottle of 7.0 mL predilute (387M-18) | |
| vial of 0.1 mL concentrate (387M-14) | |
| vial of 0.5 mL concentrate (387M-15) | |
| vial of 1.0 mL concentrate (387M-16) | |
| Quality Level | 100  |
| 500 |
|
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | 2-8°C |
| technique(s) | immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100 |
| visualization | nuclear |
| General description: | Olig2, a basic helix–loop–helix transcription factor, is involved in oligodendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, subependymomas, medulloblastomas, and nonneuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid/rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue (gliosis). In order to characterize cellular subtypes that constitute astrocytomas, oligoastrocytomas and oligodendrogliomas, double labeling of Olig2 and GFAP has been performed which identified two phenotypically distinct tumor populations. The first is Olig2+/GFAP– which has an oligodendroglial morphology, corresponding to pure oligodendrogliomas that contain only oligodendroglial cells; the second is Olig2–/GFAP+ which has an astrocytic phenotype, including not only oligoastrocytomas, but also WHO astrocytomas. Depending on proportion and spatial clustering of the two phenotypically distinct tumor populations, the tumor (Olig2-/GFAP+) is classified either as an astrocytoma when both populations are intermingled with a dominance of GFAP+ cells or oligoastrocytoma when there is some degree of spatial clustering of the GFAP+ cells. | ||||
| Legal Information: | Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany | ||||
| Linkage: | Olig2 Positive Control Slides, Product No. 387S , are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections). |
||||
| Other Notes: | For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com | ||||
| Physical form: | Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide | ||||
| Preparation Note: | Download the IFU specific to your product lot and format  Note: This requires a keycode which can be found on your packaging or product label. |
||||
| Quality: |
|
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |